1h Free Analyst Time
The Antimicrobial Resistance Surveillance Market grew from USD 5.60 billion in 2023 to USD 5.96 billion in 2024. It is expected to continue growing at a CAGR of 6.49%, reaching USD 8.71 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
The primary application of antimicrobial resistance surveillance is to provide information on the prevalence of resistant pathogens in various settings such as hospitals, community health centers, food production facilities, animal husbandry operations, water treatment plants, and environmental samples. The increasing prevalence of multidrug-resistant organisms worldwide necessitates constant monitoring to adapt existing treatments appropriately. Advances in molecular diagnostics techniques enable early detection and identification of antibiotic-resistant strains. Addtionally, growing awareness about antibiotic stewardship programs among healthcare professionals encourages prudent prescribing practices. Despite the growth prospects, several challenges hinder the antimicrobial resistance surveillance market progress. Inadequate infrastructure and funding in low and middle-income countries result in limited surveillance capabilities. Variability in laboratory methodologies employed worldwide hampers comparability of results across regions. However, the emergence of point-of-care testing devices expedites diagnosis and enables personalized treatment decisions. Harnessing genomic sequencing technologies allows for accurate tracking of resistance mechanisms and transmission dynamics at a population level. Along with these, to sustain business growth and contribute to global health security, stakeholders should focus on key areas like refining diagnostic tools for faster detection, exploring unconventional treatment approaches, utilizing artificial intelligence for predictive modeling.
Regional Insights
Antimicrobial resistance (AMR) has emerged as a significant public health threat across the Americas and Europe. Continuous surveillance of AMR is crucial in understanding the growing impact on healthcare systems, guiding policy decisions, and implementing effective strategies to mitigate the risks associated with resistant infections. The major driving factors behind increased AMR levels in the Americas and Europe include the overuse and misuse of antimicrobials in human medicine, veterinary practice, agriculture, and food production sectors. In developed countries across the Americas and Europe, stringent regulatory frameworks govern the actions of manufacturers and providers of antimicrobial products. The potential associated with emerging countries in addressing AMR is immense due to factors such as rapid economic growth, increasing healthcare expenditure, and favorable government policies. Emerging economies like India, China, and Brazil are investing heavily in R&D for antimicrobial resistance surveillance and promoting public-private partnerships to address the issue. Governments provide financial support for research and development (R&D) efforts to incentivize innovation in addressing antimicrobial resistance. For instance, in August 2023, the UK government made a significant investment of £210 million to enhance global surveillance of drug-resistant bacteria, a critical aspect of Antimicrobial Resistance (AMR) surveillance. However, initiatives focusing on surveillance systems enhancement, regulatory oversight improvements, investment in research, and development of new treatments are crucial to combating this threat effectively.Market Insights
Market Dynamics
- The market dynamics represent an ever-changing landscape of the Antimicrobial Resistance Surveillance Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
Market Drivers
- Increasing prevalence of infections caused by pathogens
- Rising government initiatives to improve the quality of diagnostics and point-of-care diagnosis
Market Restraints
- High cost associated with antimicrobial resistance surveillance
Market Opportunities
- Growing demand for advanced diagnostic solutions to manage Antimicrobial Resistance (AMR) infections
- Increasing regulatory approvals of diagnostics products worldwide
Market Challenges
- Lack of standardized methods and guidelines for AMR surveillance
Market Segmentation Analysis
- Component: Significant role of diagnostic kits in offering rapid detection of specific resistance markers at relatively lower costs
- End-User: Increasing incidence of hospital-acquired infections developed necessities for next generation antimicrobial resistance (AMR) surveillance
Industry Insights
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antimicrobial Resistance Surveillance Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antimicrobial Resistance Surveillance Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Recent Developments
Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals
Novo Holdings acquired Paratek Pharmaceuticals for USD 462 million, which signifies a major achievement in Novo Holdings' ongoing efforts to combat antimicrobial resistance. Through this acquisition, Novo Holdings gains access to a portfolio of commercial-stage biopharmaceuticals dedicated to developing treatments for life-threatening diseases and other public health threats. This move reinforces Novo Holdings' commitment to addressing the urgent need for innovative solutions in the fight against antimicrobial resistance. By leveraging their expertise and resources, Novo Holdings aims to improve patient outcomes and safeguard public health significantly.AMR Action Fund announces more investments to combat antibiotic resistance
Antimicrobial Resistance Surveillance The Action Fund for Antimicrobial Resistance (AMR) has made recent additions to its investment portfolio, including Vedanta Biosciences and Pattern Bioscience. Vedanta Biosciences is focused on developing a microbiome-directed therapy to address recurrent Clostridioides difficile infection (rCDI). On the other hand, Pattern Bioscience is dedicated to creating a diagnostics platform that can rapidly identify bacterial pathogens and determine their antibiotic susceptibility.Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antimicrobial Resistance Surveillance Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.Key Company Profiles
The report delves into recent significant developments in the Antimicrobial Resistance Surveillance Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Inc., Becton, Dickinson and Company, bioMérieux SA, Cepheid, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Liofilchem S.r.l., Lumed, Luminex Corporation, Merck & Co., Inc., Novo Holdings A/S, OpGen, Inc., Pfizer Inc., QIAGEN GmbH, Sanofi S.A., Thermo Fisher Scientific Inc., Venatorx Pharmaceuticals, Inc., Viatris Inc., Vivli Inc., and Wolters Kluwer N.V..Market Segmentation & Coverage
This research report categorizes the Antimicrobial Resistance Surveillance Market to forecast the revenues and analyze trends in each of the following sub-markets:Component
- Diagnostic Kits
- Diagnostic Systems
- Services
- Software
End-User
- Hospitals
- Research & Academic Institutes
Region
Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Additional Product Information:
- The purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
- With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase
- Purchase of this report includes 1 year online access with quarterly updates
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website
Table of Contents
1. Preface
2. Research Methodology
5. Market Insights
6. Antimicrobial Resistance Surveillance Market, by Component
7. Antimicrobial Resistance Surveillance Market, by End-User
8. Americas Antimicrobial Resistance Surveillance Market
9. Asia-Pacific Antimicrobial Resistance Surveillance Market
10. Europe, Middle East & Africa Antimicrobial Resistance Surveillance Market
11. Competitive Landscape
12. Competitive Portfolio
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Accelerate Diagnostics, Inc.
- Becton, Dickinson and Company
- bioMérieux SA
- Cepheid
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline PLC
- Johnson & Johnson Services Inc.
- Liofilchem S.r.l.
- Lumed
- Luminex Corporation
- Merck & Co., Inc.
- Novo Holdings A/S
- OpGen, Inc.
- Pfizer Inc.
- QIAGEN GmbH
- Sanofi S.A.
- Thermo Fisher Scientific Inc.
- Venatorx Pharmaceuticals, Inc.
- Viatris Inc.
- Vivli Inc.
- Wolters Kluwer N.V.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 198 |
Published | June 2024 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 5.96 Billion |
Forecasted Market Value ( USD | $ 8.71 Billion |
Compound Annual Growth Rate | 6.4% |
Regions Covered | Global |
No. of Companies Mentioned | 22 |